肺瘤消积方对痰瘀互结型非小细胞肺癌患者肿瘤标志物的影响  

The effects of the Feiliu Xiaoji decoction on tumor markers in patients with the sputum and stasis conglutination type of non-small cell lung cancer

作　　者：董雪珊 王振强 张庆江 陈晶晶 赵阳 李小江[3] 赵芳 李莹 Dong Xueshan

机构地区：[1]承德医学院,河北承德067000 [2]河北中医学院附属沧州中西医结合医院,河北沧州061000 [3]天津中医药大学第一附属医院,天津300000 [4]河北中医学院研究生学院,河北石家庄050051

出　　处：《中医临床研究》2021年第14期34-37,共4页Clinical Journal Of Chinese Medicine

基　　金：河北省中医药管理局课题。肺瘤消积方治疗痰瘀互结型晚期非小细胞肺癌临床观察(2019271)。

摘　　要：目的:观察肺瘤消积方对痰瘀互结型非小细胞肺癌患者肿瘤标志物的影响。方法:随机选择2018年1月-2019年1月至河北省沧州中西医结合医院行晚期非小细胞肺癌化疗治疗患者100例进行本次研究。使用随机数字法将患者分为观察组和对照组,各50例,所有患者均采用常规方案化疗,对照组患者给予常规止呕、护肝、护胃治疗,观察组患者在对照组治疗方案的基础上给予中药汤剂肺瘤消积方进行治疗。化疗4周期后,观察相关指标。比较两组患者临床疗效、Karnofsky功能状态评分法(Karnofsky Performance Status,KPS)评分、肿瘤标志物变化情况。结果:观察组治疗总有效率明显高于对照组,且差异具有统计学意义(P<0.05);两组患者治疗前肿瘤最大径无明显差异(P>0.05),治疗后与治疗前相比均明显缩小(P<0.05),观察组小于对照组,差异具有统计学意义(P<0.05);两组患者化疗前KPS评分无明显差异(P>0.05),治疗后观察组评分明显高于对照组,且差异具有统计学意义(P<0.05),从组内情况来看,两组治疗后KPS评分低于化疗前(P<0.05);两组患者化疗前细胞角蛋白19片段抗原(Cytokeratin 19 Fragment of an Antigen,CYFRA21-1)、神经元特异性烯醇化酶(Neuron Specific Enolase,NSE)、癌胚抗原(Carcinoembryonic Antigen,CEA)、糖抗原125(Carbohydrate Antigen 125,CA125)水平无明显差异(P>0.05),化疗2个疗程后两组患者上述肿瘤标志物与化疗前相比均明显降低(P<0.05),观察组低于对照组,组间差异显著(P<0.05)。结论:肺瘤消积方对降低痰瘀互结型非小细胞肺癌患者肿瘤标志物具有积极的作用,同时能够提高化疗的疗效,改善生活质量,因此具有重要的临床应用价值。Objective:To observe the effects of the Feiliu Xiaoji decoction(肺瘤消积方)on tumor markers in patients with the sputum and stasis conglutination type of non-small cell lung cancer.Methods:100 cases were divided into the observation group and the control group according to the random number table method,50 cases in each.All the cases were treated by conventional chemotherapy.The patients in the control group were treated by conventional antiemetic,liver protection and stomach protection.The patients in the observation group were treated with the Feiliu Xiaoji decoction more.After 4 cycles of chemotherapy,the related indexes were observed.Results:The total efficiency in the observation group was significantly higher than that in the control group,and there was a statistical difference(P<0.05).There was no significant difference in the maximum diameter of tumor between the groups before treatment(P>0.05).After treatment,the maximum diameter of tumor in the groups were significantly smaller than before treatment(P<0.05),and those in the observation group was smaller than the control group,with a statistical difference(P<0.05).After chemotherapy,KPS score in the groups was lower than before,and the KPS score in the observation group was significantly higher than the control group,and there was a statistically significant difference(P<0.05).There was no significant difference in CYFRA21-1,NSE,CEA,CA125 levels between the groups before chemotherapy(P>0.05).After 2 courses of chemotherapy,the above tumor markers in the groups were lower than before,and in the observation group were lower than the control group,with a statistically significant difference(P<0.05).Conclusion:The Feiliu Xiaoji decoction shows a positive effect on reducing tumor markers in patients with the sputum and stasis conglutination type of non-small cell lung cancer,and can improve the curative effect of chemotherapy and the life quality of patients,so it has an important clinical application value.

关 键 词：肺瘤消积方 痰瘀互结 非小细胞肺癌 肿瘤标志物 

分 类 号：R563[医药卫生—呼吸系统]